[Effect of lovastatin on platelet function in hypercholesterolemic patients]. 1992

A Dmoszyñska, and A Kleinrok, and P Dabrowski, and I Sokoluk, and M Markiewicz, and A Ledwozyw, and B Sokołowska
Kliniki Hematologii AM, Lublinie.

18 patients were studied with primary hypercholesterolemia (type II according to Fredricksen) and fasting cholesterol level during low fat diet above 250 mg/dl. Blood samples were taken: I--before lovastatin administration on diet, II--after 4 weeks administration of 20 mg, III--after 4 weeks of 80 mg and IV--4 weeks after the drug discontinued. The following tests were performed: platelets aggregation induced by ADP and adrenaline, PF3 and PF4, platelet MDA, serum triglycerides, total cholesterol, HDL-cholesterol and LDL-cholesterol. Before treatment patients showed significant platelets hyperaggregation and MDA concentration comparing to the control group. During the drug administration significant lowering of platelets MDA concentration, was observed small but significant HDL cholesterol level increase which correlated with platelet MDA concentration. Availability of PF3 and release of PF4 did not change during study.

UI MeSH Term Description Entries
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008148 Lovastatin A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver. Lovastatin, 1 alpha-Isomer,Mevinolin,6-Methylcompactin,Lovastatin, (1 alpha(S*))-Isomer,MK-803,Mevacor,Monacolin K,1 alpha-Isomer Lovastatin,6 Methylcompactin,Lovastatin, 1 alpha Isomer,MK 803,MK803,alpha-Isomer Lovastatin, 1
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006937 Hypercholesterolemia A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population. Hypercholesteremia,Elevated Cholesterol,High Cholesterol Levels,Cholesterol Level, High,Cholesterol Levels, High,Cholesterol, Elevated,Cholesterols, Elevated,Elevated Cholesterols,High Cholesterol Level,Hypercholesteremias,Hypercholesterolemias,Level, High Cholesterol,Levels, High Cholesterol
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A Dmoszyñska, and A Kleinrok, and P Dabrowski, and I Sokoluk, and M Markiewicz, and A Ledwozyw, and B Sokołowska
January 1994, Metabolism: clinical and experimental,
A Dmoszyñska, and A Kleinrok, and P Dabrowski, and I Sokoluk, and M Markiewicz, and A Ledwozyw, and B Sokołowska
January 1995, Pharmacotherapy,
A Dmoszyñska, and A Kleinrok, and P Dabrowski, and I Sokoluk, and M Markiewicz, and A Ledwozyw, and B Sokołowska
January 1998, International journal of tissue reactions,
A Dmoszyñska, and A Kleinrok, and P Dabrowski, and I Sokoluk, and M Markiewicz, and A Ledwozyw, and B Sokołowska
January 1992, Clinical therapeutics,
A Dmoszyñska, and A Kleinrok, and P Dabrowski, and I Sokoluk, and M Markiewicz, and A Ledwozyw, and B Sokołowska
November 1999, Thrombosis research,
A Dmoszyñska, and A Kleinrok, and P Dabrowski, and I Sokoluk, and M Markiewicz, and A Ledwozyw, and B Sokołowska
June 1992, Kardiologiia,
A Dmoszyñska, and A Kleinrok, and P Dabrowski, and I Sokoluk, and M Markiewicz, and A Ledwozyw, and B Sokołowska
June 1993, Journal of clinical pharmacology,
A Dmoszyñska, and A Kleinrok, and P Dabrowski, and I Sokoluk, and M Markiewicz, and A Ledwozyw, and B Sokołowska
January 1996, Archives of gerontology and geriatrics,
A Dmoszyñska, and A Kleinrok, and P Dabrowski, and I Sokoluk, and M Markiewicz, and A Ledwozyw, and B Sokołowska
January 1992, Clinical therapeutics,
A Dmoszyñska, and A Kleinrok, and P Dabrowski, and I Sokoluk, and M Markiewicz, and A Ledwozyw, and B Sokołowska
May 2011, European journal of pharmacology,
Copied contents to your clipboard!